6.64
1.22%
+0.08
Ironwood Pharmaceuticals Inc stock is currently priced at $6.64, with a 24-hour trading volume of 2.03M.
It has seen a +1.22% increased in the last 24 hours and a -15.84% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $6.67 pivot point. If it approaches the $6.44 support level, significant changes may occur.
Previous Close:
$6.56
Open:
$6.55
24h Volume:
2.03M
Market Cap:
$1.06B
Revenue:
$442.74M
Net Income/Loss:
$-1.00B
P/E Ratio:
-1.0993
EPS:
-6.04
Net Cash Flow:
$183.15M
1W Performance:
-1.48%
1M Performance:
-15.84%
6M Performance:
-29.66%
1Y Performance:
-34.26%
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
301 Binney Street, Cambridge, MA
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-17-24 | Initiated | Craig Hallum | Buy |
Dec-14-23 | Initiated | Wells Fargo | Overweight |
Nov-09-23 | Initiated | Jefferies | Buy |
Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
Sep-02-22 | Initiated | CapitalOne | Overweight |
Apr-22-22 | Initiated | Piper Sandler | Overweight |
Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jun-17-20 | Initiated | Northland Capital | Outperform |
Jul-10-19 | Resumed | Credit Suisse | Neutral |
Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
Jul-23-18 | Initiated | H.C. Wainwright | Sell |
May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
May-03-17 | Initiated | Wells Fargo | Outperform |
Apr-07-17 | Reiterated | Mizuho | Buy |
Feb-22-17 | Reiterated | Barclays | Equal Weight |
Nov-04-16 | Reiterated | Mizuho | Buy |
Oct-24-16 | Reiterated | Wedbush | Neutral |
Oct-10-16 | Reiterated | Mizuho | Buy |
Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 2.4% - MarketBeat
MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) PT Lowered to $14.00 at Craig Hallum - Defense World
Defense World
The 3.7% return this week takes Ironwood Pharmaceuticals' (NASDAQ:IRWD) shareholders three-year gains to 25% - Yahoo Canada Shine On
Yahoo Canada Shine On
US$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest Results - Yahoo Finance
Yahoo Finance
Objective long/short (IRWD) Report - Stock Traders Daily
Stock Traders Daily
Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results, Misses Expectations By $0.20 EPS - MarketBeat
MarketBeat
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Ironwood Pharmaceuticals Inc (IRWD) Revenue 2024
IRWD reported a revenue (TTM) of $442.74 million for the quarter ending December 31, 2023, a +7.83% rise year-over-year.
Ironwood Pharmaceuticals Inc (IRWD) Net Income 2024
IRWD net income (TTM) was -$1.00 billion for the quarter ending December 31, 2023, a -672.50% decrease year-over-year.
Ironwood Pharmaceuticals Inc (IRWD) Cash Flow 2024
IRWD recorded a free cash flow (TTM) of $183.15 million for the quarter ending December 31, 2023, a -33.06% decrease year-over-year.
Ironwood Pharmaceuticals Inc (IRWD) Earnings per Share 2024
IRWD earnings per share (TTM) was -$6.51 for the quarter ending December 31, 2023, a -771.13% decline year-over-year.
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and Nicox SA to generate various therapeutics for the treatment of certain ophthalmic conditions, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):